Grants for Biotech and Life Sciences in Belgium

Belgium is one of Europe's leading life sciences hubs, with a dense concentration of pharma headquarters, biotech startups, clinical research organizations, and university spin-offs. This ecosystem is not accidental — it is supported by a layered public funding system that combines regional innovation grants, federal tax incentives, and EU-level research programs.

For biotech and life sciences companies, the standard innovation grant landscape applies, but there are also programs and funding mechanisms specifically designed for health, pharma, med-tech, and biological research. Understanding which programs are sector-specific and which are general-purpose is the first step toward building a strong funding strategy.

This guide covers the key Belgian and EU funding instruments available to life sciences companies in 2026, with practical detail on eligibility, amounts, and how these programs differ from standard innovation support. If you are unsure which grants match your company, use the BelGrant assistant for a personalized recommendation.

Innoviris, the Brussels-Capital Region's innovation agency, operates several programs relevant to biotech and life sciences. The Innoviris Research & Innovation calls regularly include health and biotech as priority themes. Companies based in Brussels working on diagnostics, therapeutics, medical devices, or digital health can apply for project funding covering up to 50% of eligible R&D costs for SMEs, with maximum grants typically ranging from €100,000 to €500,000 depending on the call.

Innoviris also supports collaborative research between Brussels-based companies and universities or hospitals through its co-creation and joint R&D instruments. For early-stage biotech companies, the Proof of Concept program can fund initial validation work — testing whether a biological compound, diagnostic method, or medical device concept has commercial potential before committing to full-scale development.

A key advantage of Innoviris for life sciences is the agency's familiarity with long development timelines typical in biotech. Evaluators understand that a biotech project may take years to reach market, which is reflected in how they assess project feasibility and impact. However, you must still demonstrate a clear path from the funded research to a commercial outcome. Companies in the preclinical or early clinical stage should articulate their regulatory strategy and timeline as part of the application.

VLAIO (Flanders Innovation & Entrepreneurship) is the primary funding agency for Flemish companies, and its R&D project grants and development grants are heavily used by the biotech sector. Flanders is home to major life sciences clusters including those around Ghent, Leuven, and Antwerp, and VLAIO's programs are well-calibrated for the needs of research-intensive companies.

The VLAIO O&O (Onderzoek & Ontwikkeling) subsidy funds industrial research and experimental development. For biotech SMEs, the intervention rate can reach up to 50% for industrial research and 25–35% for experimental development, with maximum project budgets that can exceed €1 million for ambitious multi-year projects. Personnel costs, lab equipment, consumables, subcontracting, and IP costs are typically eligible.

What makes VLAIO particularly relevant for biotech is the integration with the broader Flemish innovation ecosystem. Flanders Bio, the life sciences industry association, works closely with VLAIO and can help companies navigate the application process, connect with academic partners, and position their projects within Flanders' strategic research priorities. Companies that align their projects with Flemish specialisation domains — particularly health and biotechnology — may receive higher evaluation scores.

VLAIO also offers the KMO-portefeuille for smaller advisory and training needs, and the SME Growth subsidy for scaling biotech companies that need to hire specialized personnel or access international markets. These are not R&D grants per se, but they complement the innovation funding by supporting the commercial development side of a biotech business.

The Belgian federal R&D tax credit is one of the most significant funding mechanisms for life sciences companies, though it operates differently from direct grants. The partial exemption from payment of withholding tax on salaries of R&D personnel allows qualifying companies to retain up to 80% of the withholding tax on wages paid to researchers holding specific qualifications (master's or PhD in exact sciences, engineering, medicine, or related fields).

For biotech and pharma companies with large R&D teams, this can represent hundreds of thousands of euros in annual savings. The exemption applies to personnel working on R&D projects that meet the Belspo (Belgian Science Policy Office) definition of research and development. Life sciences research — drug discovery, clinical development, bioprocess engineering, diagnostics development — typically qualifies without difficulty.

Additionally, the innovation income deduction allows companies to deduct up to 85% of net income derived from patents, supplementary protection certificates, and certain other IP rights. For pharma and biotech companies that have successfully developed and patented compounds or technologies, this can dramatically reduce the effective tax rate on commercialized innovations. The combination of the R&D wage tax exemption and the innovation income deduction makes Belgium one of the most tax-efficient locations in Europe for life sciences R&D.

Unlike regional grants, the federal tax credit does not require an application to a funding agency. Instead, companies claim it through their tax filings. However, you must register qualifying R&D projects with Belspo and maintain proper documentation of R&D activities and personnel allocation. Getting this documentation right from the start is critical — retroactive claims are possible but more complex to substantiate. See our guide to R&D grants in Belgium for more detail on how these mechanisms interact.

Horizon Europe, the EU's framework programme for research and innovation (2021–2027), includes a dedicated Health cluster (Cluster 1) with a budget exceeding €8 billion over the programme period. Belgian biotech and life sciences companies — particularly those collaborating with research institutions — are well-positioned to access this funding.

The Health cluster funds projects in areas including infectious diseases, cancer, rare diseases, digital health, health data, and personalized medicine. Projects are typically collaborative, involving consortia of companies, universities, and hospitals from multiple EU member states. The funding rate for SMEs can reach 70% of eligible costs, making Horizon Europe one of the most generous funding instruments available.

Belgian companies have a strong track record in Horizon Europe health calls, partly because of the country's dense network of clinical research centres, university hospitals, and contract research organizations. National Contact Points (NCPs) at Belspo and the regional agencies can help companies identify suitable calls and find consortium partners.

Beyond Horizon Europe, the European Innovation Council (EIC) Accelerator provides grants and equity investments for breakthrough health innovations. The EIC Accelerator offers up to €2.5 million in grant funding plus up to €15 million in equity, specifically targeting companies with innovations that are too risky for standard venture capital. Biotech companies in the preclinical or early clinical stage are a core target audience for this instrument. For a broader view of innovation funding options, see our innovation grants overview.

Life sciences grants differ from standard innovation grants in several important ways. First, evaluators typically accept longer project timelines. A software innovation project might be expected to reach market within 12–18 months, but a biotech project may have a 5–10 year horizon. Grant programs recognize this, but you must still demonstrate clear milestones and intermediate deliverables within the grant period.

Second, eligible costs often include specialized items that are rare in other sectors: clinical trial costs, regulatory filing fees, biological materials, clean room equipment, and GMP (Good Manufacturing Practice) facility costs. Not all programs cover all of these, so review the eligible cost categories carefully for each program.

Third, the co-financing landscape is different. Biotech companies often combine public grants with venture capital, pharma partnerships, and EU funding in complex stacking arrangements. Understanding the de minimis rules and state aid cumulation limits is essential when layering multiple funding sources. Belgian grants generally count toward state aid limits, and exceeding the ceiling can result in clawback obligations.

Finally, the evaluation criteria often weight scientific excellence more heavily than in standard business innovation programs. Having strong academic partnerships, published research, or preliminary IP filings strengthens a life sciences application significantly. If you are not sure whether your company qualifies for biotech-specific funding, start with the BelGrant assistant for a quick assessment of your eligibility across all available programs.